Credit score: Pixabay/CC0 Public Area
Weight-loss treatment has taken the world by storm and helped many obese individuals. However for some, important weight reduction additionally comes with a lack of muscle mass and might result in an elevated danger of osteoporosis.
New analysis now means that the drug bimagrumab might be able to alleviate a few of this danger, say Ph.D. scholar Frederik Duch Bromer and postdoc Andreas Lodberg from the Division of Biomedicine at Aarhus College, who’re behind the examine.
The work is revealed within the Journal of Cachexia, Sarcopenia and Muscle.
“We are the first to study how certain drugs affect bones, and the results show that bimagrumab can increase the amount of bone tissue while building muscle mass, and this could be very important for the many people currently taking weight-loss medication,” say the authors.
Bimagrumab was initially developed to deal with muscle loss and dysfunction, however since then, it has turn into obvious that it additionally has a fat-burning element to it. So, if permitted, it might be a part of a second-generation weight reduction drug available on the market.
“Therefore, it’s relevant to research how this particular patient group reacts to the drug,” says Lodberg. “An estimated two billion people will be categorized as overweight by 2035, so it’s also important that we research the drugs that come on the market for this particular patient group in order to better understand their long-term impact on the body.”
Muscle parameters. Credit score: Journal of Cachexia, Sarcopenia and Muscle (2025). DOI: 10.1002/jcsm.13718
Osteoporosis can show pricey for sufferers and society
Sufferers on weight-loss treatment usually have a historical past of weight fluctuation, which might contribute to the event of osteoporosis. Brittle bones enhance the chance of significant fractures, and that is pricey for each sufferers and society.
“Bimagrumab slightly increases the calcium content in bones and promotes the formation of new bone in what we call the shell (cortex) of the long bones. We also saw a significant build-up of bone tissue in the area around the femoral head, which is typically where many older people incur fractures,” Bromer says.
In accordance with Bromer, the outcomes additionally confirmed that bimagrumab has no impact on the blood. Related medication have beforehand been proven to extend purple blood cell manufacturing, growing the chance of blood clots.
The examine is predicated on mice with each osteoporosis and lowered muscle mass, and the drug is now being examined in a number of section 2 scientific trials. Lodberg emphasizes that extra analysis is required: “Our study shows that bimagrumab has a positive effect in many areas, but we also have indications that the drug may have other side effects, and we’ll now investigate this further to get a clearer picture of the implications of using the drug for patients.”
Lodberg and Bromer hope to have the ability to proceed with additional analysis to analyze each the optimistic outcomes and doable unintended effects.
Extra info:
Frederik Duch Bromer et al, The Impact of Anti‐Activin Receptor Kind IIA and Kind IIB Antibody on Muscle, Bone and Blood in Wholesome and Osteosarcopenic Mice, Journal of Cachexia, Sarcopenia and Muscle (2025). DOI: 10.1002/jcsm.13718
Supplied by
Aarhus College
Quotation:
Drug might counteract muscle loss and osteoporosis after speedy weight reduction (2025, February 10)
retrieved 11 February 2025
from https://medicalxpress.com/information/2025-02-drug-counteract-muscle-loss-osteoporosis.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
